VIA
IMMU

Vantage Investment Advisors’s Immunomedics Inc IMMU Stock Holding History

Vantage Investment Advisors’s Portfolio IMMU Stock Details IMMU Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-248
Closed -$6K – 822
2018
Q2 		$6K Buy
+248
New +$4.98K ﹤0.01% 622
2016
Q1 		– Sell
-160
Closed – – 863
2015
Q4 		$0 Hold
160
– – ﹤0.01% 836
2015
Q3 		$0 Buy
+160
New +$408 ﹤0.01% 820

Other funds holding IMMU

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Vantage Investment Advisors's IMMU Position: Q3 2018 in Review

Vantage Investment Advisors sold out of Immunomedics Inc (IMMU) in Q3 2018, closing a stake of 248 shares — an estimated $6K sold.

Vantage Investment Advisors first reported a position in IMMU in Q3 2015 and held it in 3 quarters. The position peaked at $6K in Q2 2018. 207 funds tracked by Wall St. Rank hold IMMU as of Q3 2018.

  • Vantage Investment Advisors reported no remaining Immunomedics Inc position as of Q3 2018 after selling out during the quarter.
  • Vantage Investment Advisors sold 248 Immunomedics Inc shares in Q3 2018, an estimated $6K.
  • Vantage Investment Advisors first reported a position in Immunomedics Inc in Q3 2015 and held it in 3 quarters.
  • Vantage Investment Advisors's Immunomedics Inc position peaked at $6K in Q2 2018.
  • 207 funds tracked by Wall St. Rank held Immunomedics Inc as of Q3 2018.

Based on Vantage Investment Advisors's 13F filing for Q3 2018, filed 9 Nov 2018.